Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04650555 · ClinicalTrials.gov registry record · Phase 1
BIO 300 Oral Powder Safety and Pharmacokinetics
A Phase 1 study of Acute Radiation Syndrome, sponsored by Humanetics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT04650555 is a Phase 1 study of Acute Radiation Syndrome that has completed, run by Humanetics Corporation. The registered enrollment target is 34 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04650555, a Phase 1 study of Acute Radiation Syndrome, has completed, sponsored by Humanetics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given daily for 6 consecutive days.
Conditions Studied
Interventions
- DRUG BIO 300 Oral Powder
Study Locations (1)
Minnesota
- Nucleus Network, Ltd (Formally Prism Research, LLC) - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04650555
The ClinicalTrials.gov registry entry for NCT04650555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Humanetics Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Radiation Syndrome appearing as the primary indexed condition, and to 1 intervention - of which BIO 300 Oral Powder is the first listed.
NCT04650555 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04650555 about?
NCT04650555 is a clinical study titled "BIO 300 Oral Powder Safety and Pharmacokinetics". Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given...
What is the current status of trial NCT04650555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2020-12-08. Estimated completion is 2021-07-06.
What conditions does trial NCT04650555 study?
This clinical trial studies the following conditions: Acute Radiation Syndrome.
What interventions are being tested in trial NCT04650555?
The interventions under investigation include: BIO 300 Oral Powder (DRUG).
Who is sponsoring clinical trial NCT04650555?
This trial is sponsored by Humanetics Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04650555 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.